Innovation is being used to improve quality metrics in oncology care at the patient forefront and in data, explained Lani M. Alison, BSN, MS, HCQ, PCMH, CCE, vice president of Clinical Affairs, Regional Cancer Care Associates.
Innovation is being used to improve quality metrics in oncology care when it comes to the patient and in data, explained Lani M. Alison, BSN, MS, HCQ, PCMH, CCE, vice president of Clinical Affairs, Regional Cancer Care Associates.
Transcript
How is innovation being used to improve quality metrics in oncology care?
Innovation is being used in many different ways. There’s innovation at the patient forefront, and then there’s also innovation in data. So, what I really deal with is pretty much data that is then translated into the practice, and we need to have evidence-based data in studies that is really written by innovation. When we have innovative patient assistance, for example, or innovative strategies to improve patient outcomes, this has really been very helpful. When we say, “so is this an innovation or is this what we have done before?” innovation can be a new way of doing things from already proven tactics.
For example, care management. Care management was an innovation a few years ago, maybe 10 years ago, so we then improved it to care coordination. When we care manage patients, it’s not only with a provider that has given the opportunity to care manage a patient, but also it goes beyond that to other providers that are also taking care of the patients. So, that is an innovation in the way we manage patients outside of the acute care facilities.
Managed Care Cast Presents: BTK Inhibitors in Treatment-Naive Patients With CLL and MCL
December 26th 2024A trio of experts discuss the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) with Bruton tyrosine kinase (BTK) inhibitors, including cost considerations.
Listen
HS Treatment Goals: Better Quality of Life, Not Just Control
January 3rd 2025For part 3 of our discussion with Chris Sayed, MD, we tackle several important topics in the hidradenitis suppurative (HS) and inflammatory disease space: patient quality of life, medication and treatment goals, and the possibility of a cure.
Read More
Dr Yehuda Handelsman: DCRM Guidelines Are Shaping Integrated, Global CRM Care
January 3rd 2025In part 2 of our interview, Yehuda Handelsman, MD, discusses how cardiorenalmetabolic (CRM) disease management is advancing with the 2022 Diabetes, Cardiorenal, and Metabolic (DCRM) multispecialty practice recommendations and the updated DCRM 2.0 guidelines.
Read More